Natural course of subclinical hyperthyroidism in primary care in the Netherlands
European Thyroid Journal · 01.12.2025 · 14 (6)
DOI: 10.1530/etj-25-0142 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, online erschienen am 05.11.2025. Verfasst von Stan R Ursem und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Location University of Amsterdam and Location Vrije Universiteit Amsterdam, A…. Hauptthemen laut MEDLINE: Hyperthyroidism, Primary Health Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Subclinical hyperthyroidism (SHT), a low serum thyroid-stimulating hormone (TSH) and normal free thyroxine (FT4) concentration, has potential health implications, yet the epidemiology and factors influencing its natural course in a primary care setting remain unclear.
Objectives
To investigate the incidence and natural course of SHT in primary care and assess guideline adherence to follow-up recommendations within Dutch primary care.
Methods
Using a retrospective cohort design in general practitioner data from the PHARMO Data Network in the Netherlands (2012–2021), patients with biochemically confirmed SHT were followed to assess progression to hyperthyroidism, recovery, or persistence. Adherence to the Dutch primary care SHT guideline was evaluated.
Results
The SHT annual incidence was approximately 200 per 100,000 person-years. Among the 11,163 SHT patients, 47% recovered, 11% persisted, and 8% progressed to overt hyperthyroidism over a median follow-up of 5 years. Lower TSH (<0.1 mU/L) and female sex were associated with lower odds of recovery (OR for TSH <0.1 mU/L: 0.50, 95% CI: 0.43–0.58; OR for women: 0.82, 95% CI: 0.70–0.96) and higher odds of progression to overt hyperthyroidism (OR for TSH <0.1 mU/L: 2.36, 95% CI: 1.97–2.83; OR for women: 1.69, 95% CI: 1.32–2.17). Guideline adherence evaluation showed that 33% received follow-up TSH measurement within 6 months, and 4% underwent TSH-receptor antibody testing.
Conclusion
This study highlights that a small subset of SHT patients progress to overt hyperthyroidism. Factors increasing the odds for progression included lower baseline TSH and female sex. Our findings indicate a need for improved guideline adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrine Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Location University of Amsterdam and Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands.
- Department of General Practice, Location Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
- Laboratory Specialized Diagnostics & Research, Department of Laboratory Medicine, Location University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
- Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
- PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.
ORCID-Profile: Stan R Ursem, Jesse M van den Berg, Anita Boelen, Annemieke C Heijboer
Zitieren
APA
Ursem, S. R., den Elzen, W. P. J., van den Berg, J. M., Boelen, A., Elders, P. J. M., Noordam, R., & Heijboer, A. C. (2025). Natural course of subclinical hyperthyroidism in primary care in the Netherlands. European Thyroid Journal, 14(6). https://doi.org/10.1530/etj-25-0142
Vancouver
Ursem SR, den Elzen WPJ, van den Berg JM, Boelen A, Elders PJM, Noordam R, et al. Natural course of subclinical hyperthyroidism in primary care in the Netherlands. European Thyroid Journal. 2025;14(6). doi:10.1530/etj-25-0142
BibTeX
@article{Ursem2025,
author = {Ursem, Stan R and den Elzen, Wendy P J and van den Berg, Jesse M and Boelen, Anita and Elders, Petra J M and Noordam, Raymond and Heijboer, Annemieke C},
title = {Natural course of subclinical hyperthyroidism in primary care in the Netherlands},
journal = {European Thyroid Journal},
year = {2025},
volume = {14},
number = {6},
doi = {10.1530/etj-25-0142}
}
EUVIMED